Startup Vima Adds Parkinson’s to Movement Disorder Scope, Expanding Series A Round to $100M – MedCity News
When Vima Therapeutics launched last year to take its drug candidate into human testing, the lead indication was isolated dystonia,…
When Vima Therapeutics launched last year to take its drug candidate into human testing, the lead indication was isolated dystonia,…